GH earnings call for the period ending September 30, 2019.
There's nothing like triple-digit-percentage sales growth to make investors happy.
Guardant Health (GH) is up 11% premarket on light volume following its Q3 results released after the close yesterday. Highlights: Revenue: $60.8M (+180%).
Guardant Health, Inc. (NASDAQ:GH) will provide updates on colorectal cancer screening rates of its LUNAR-2 blood test when it reports third-quarter 2019 earnings results.The...
Exact Sciences Corp. (NASDAQ:EXAS) announced that the FDA has approved a label expansion of its noninvasive colorectal cancer screening test, Cologuard.The test can now be used...
For Immediate ReleaseChicago, IL – August 28, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Buy||Strong Buy||Buy||Buy||Buy|
|Technical Indicators||Sell||Strong Buy||Strong Buy||Strong Buy||Strong Buy|
|Summary||Neutral||Strong Buy||Strong Buy||Strong Buy||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Outside Down||1M||2||Sep 19|
|Advance Block Bearish||1W||2||Nov 03, 2019|
|Deliberation Bearish||1W||2||Nov 03, 2019|
|Doji Star Bearish||1W||2||Nov 03, 2019|
|Three Inside Up||30||2||Nov 15, 2019 02:30PM|
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. It provides Guardant Health Oncology Platform. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for advanced stage cancer. Its liquid biopsy tests fuels its programs developing tests for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant360 is a molecular diagnostic test that measures 73 cancer-related genes from circulating tumor deoxyribonucleic acid (ctDNA). Its Guardant360 process includes blood collection, laboratory processing, analysis and reporting. Guardant360 is used for a range of applications, including translational science research and identifying target patient populations, drug development and commercialization post-drug approval.Read More
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.